Cover Image
市場調查報告書

經皮藥物遞輸市場機會與臨床實驗平台分析

Transdermal Drug Delivery Market & Clinical Pipeline Insight

出版商 KuicK Research 商品編碼 302586
出版日期 內容資訊 英文 456 Pages
商品交期: 最快1-2個工作天內
價格
Back to Top
經皮藥物遞輸市場機會與臨床實驗平台分析 Transdermal Drug Delivery Market & Clinical Pipeline Insight
出版日期: 2014年05月01日 內容資訊: 英文 456 Pages
簡介

經皮藥物遞輸系統,過去數十年成為皮膚疾病治療的重要工具。經皮藥物遞輸法為非侵入性從皮膚表面送交藥物到循環系統。全球經皮藥物遞輸市場從2013年的250億美元成長到2018年超過400億美元的規模。

本報告提供經皮藥物遞輸市場概要、推動市場的要素與課題、臨床實驗趨勢等,以及參與企業的競爭環境彙整,為您概述為以下內容。

第1章 經皮藥物遞輸的簡介

第2章 經皮藥物遞輸的機制

  • 經皮藥物遞輸的機制
  • 貼片劑的種類

第3章 為何需要經皮藥物遞輸

第4章 經皮藥物遞輸市場預測

  • 市場概要
  • 臨床實驗平台分析

第5章 經皮藥物遞輸市場趨勢

  • 推動市場的要素
  • 應該議論課題

第6章 未來的經皮藥物遞輸市場

第7章 經皮藥物遞輸相關指南/法律規章

  • EMA的貼片劑的品質相關指南
  • FDA的經皮及相關藥物遞輸系統的餘留藥物相關指南

第8章 各相,國家,標的適應之症臨床實驗趨勢

第9章 已上市藥物簡介

第10章 中斷、中止的藥物簡介

第11章 競爭環境

  • Acrux
  • ANI Pharmaceuticals
  • Antares Pharma
  • Bayer HealthCare Pharmaceuticals
  • Dermatrends Inc.
  • Durect Corporation
  • Nuvo Research
  • Novartis
  • Phosphagenics
  • Zosano Pharma

圖表

目錄

Transdermal drug delivery system, over the past decades, has emerged as a major tool for treating diseases of the skin. The major underlying factor driving this method is that the human skin is the most readily accessible surface for the delivery of drugs. A transdermal patch is defined as a medicated adhesive patch which is placed on the skin for delivering a specific dose of medication through the layers of the skin and into the bloodstream. This patch is considered to be a self contained, discrete dosage form, when applied to the intact skin, would deliver the drug, through the skin at a controlled rate to the systemic circulation.

Transdermal drug delivery method is a non-invasive method which transports the drug from the surface of the skin to the circulatory system. The most effective medium for absorbing the drug is known to be the human skin. Patches are made on the skin through which this entire process is carried out. There are different types of patches which are used to introduce the active ingredients through the skin into the circulatory system. The transdermal delivery system broadly includes all topically administered drug formulations.

Transdermal drug delivery system has been proved to be efficient owing to its large advantages over other controlled drug delivery systems. Some of these advantages include the reduction of painful delivery and the first pass metabolism of the drugs. This system of drug delivery is considered to be user-friendly, convenient, and it offers the advantage of multi-day dosing. These factors have led to a significant increase in the rate of patient compliance.

There has been a significant upward trend in the global market for transdermal drug delivery. The market for transdermal drug delivery was worth US$ 25 billion in 2013 and is further anticipated to surpass US$ 40 billion by 2018. The major factor driving such a significant growth in the market is the increasing number of transdermal drug delivery products introduced into the market and continuously delivering therapeutic benefits in the real sense to the patients across the globe.

Inspite of the transdermal system being highly successful in niche market, in other therapeutic application areas, the growth of this segment has not been highly commendable. There is a huge potential which is attracting the various companies in the pharmaceutical and biotechnology space. There are many application areas which are currently being researched upon. Some of them are wound care, monitoring and diagnostic methods. In these areas, the skin is used as a major portal for the delivery of drugs into the human body. Thus, the application of this system of drug delivery is most likely to play a significant role in improving the quality of life.

"Transdermal Drug Delivery Market Opportunity & Clinical Pipeline Insight" Report Highlights:

  • Transdermal Drug Delivery Market Overview
  • Favorable Market Drivers & Key Issues to be Discussed
  • FDA & EMA Guidelines
  • Transdermal Drug Clinical Pipeline by Phase, Disease & Country
  • Transdermal Drug Profiles in Report: 250
  • Transdermal Drug in Clinical Phase: 87
  • Number of Marketed Transdermal Drugs: 55
  • Majority of Transdermal Drugs in Preclinical Phase: 26
  • Number of Discontinued & Suspended Drug Profiles: 108

Table of Contents

1. Introduction to Transdermal Drug Delivery

2. Transdermal Drug Delivery Mechanism

  • 2.1. Mechanisms of Transdermal Drug Delivery
  • 2.2. Types of Transdermal Patch

3. Why Need For Transdermal Drug Delivery?

4. Transdermal Drug Delivery Market Outlook

  • 4.1. Market Overview
  • 4.2. Clinical Pipeline Analysis

5. Transdermal Drug Delivery Market Dynamics

  • 5.1. Favorable Market Drivers
  • 5.2. Key Issues to be Discussed

6. Future of Transdermal Drug Delivery Market

7. Guidelines/Regulations for Transdermal Drug Delivery

  • 7.1. EMA Guideline for Quality of Transdermal Patches
  • 7.2. FDA Guidelines for Residual Drug in Transdermal & Related Drug Delivery Systems

8. Transdermal Drug Delivery Clinical Trial Insight by Phase, Country & Target Indications

  • 8.1. Unknown Phase
  • 8.2. Research
  • 8.3. Preclinical
  • 8.4. Clinical
  • 8.5. Phase I
  • 8.6. Phase I/II
  • 8.7. Phase II
  • 8.8. Phase III
  • 8.9. Preregistration
  • 8.10. Registered

9. Marketed Transdermal Drug Profiles

10. Suspended & Discontinued Transdermal Drug Profiles

  • 10.1. No Development Reported
  • 10.2. Discontinued
  • 10.3. Market Withdrawal
  • 10.4. Suspended

11. Competitive Landscape

  • 11.1. Acrux
  • 11.2. ANI Pharmaceuticals
  • 11.3. Antares Pharma
  • 11.4. Bayer HealthCare Pharmaceuticals
  • 11.5. Dermatrends Inc.
  • 11.6. Durect Corporation
  • 11.7. Nuvo Research
  • 11.8. Novartis
  • 11.9. Phosphagenics
  • 11.10. Zosano Pharma

List of Figures

  • Figure 1-1: Drug Delivery Methods
  • Figure 2-1: Transdermal Drug Delivery Mechanism
  • Figure 4-1: Composition of Drug Delivery Market
  • Figure 4-2: Global Transdermal Drug Delivery Market (US$ Billion), 2013-2018
  • Figure 4-3: Regional Market for Transdermal Drug Delivery
  • Figure 4-4: Transdermal Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-5: Number of Transdermal Drugs in Clinical Trial by Phase, 2014
  • Figure 4-6: Inactive Transdermal Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-7: Number of Inactive Transdermal Drugs in Clinical Trial by Phase, 2014
  • Figure 4-8: No Development in Transdermal Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-9: Number of No Development in Transdermal Drugs in Clinical Trial by Phase, 2014
  • Figure 4-10: Discontinued Transdermal Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-11: Number of Discontinued Transdermal Drugs in Clinical Trial by Phase, 2014
  • Figure 4-12: Suspended Transdermal Drugs in Clinical Trial by Phase (%), 2014
  • Figure 4-13: Number of Suspended Transdermal Drugs in Clinical Trial by Phase, 2014
  • Figure 6-1: Developments in Transdermal Drug Delivery
  • Figure 11-1: Acrux Clinical Pipeline
  • Figure 11-2: Antares Pharma Clinical Pipeline
  • Figure 11-3: DURECT Corporation Clinical Pipeline
  • Figure 11-4: Phosphagenics Clinical Pipeline
  • Figure 11-5: Zosano Pharma Clinical Pipeline
Back to Top